Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/162587
Title: Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial
Authors: Rao, Shripada
Esvaran, Meera
Chen, Liwei
Keil, Anthony D.
Gollow, Ian
Simmer, Karen
Wemheuer, Bernd
Conway, Patricia
Patole, Sanjay
Keywords: Engineering::Bioengineering
Issue Date: 2022
Source: Rao, S., Esvaran, M., Chen, L., Keil, A. D., Gollow, I., Simmer, K., Wemheuer, B., Conway, P. & Patole, S. (2022). Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial. Pediatric Research, 92(4), 1122-1131. https://dx.doi.org/10.1038/s41390-021-01884-x
Journal: Pediatric Research
Abstract: OBJECTIVE: To evaluate whether probiotic supplementation attenuates gut-dysbiosis in neonates with congenital gastrointestinal surgical conditions (CGISC). METHODS: Sixty-one neonates (≥35 weeks gestation) with CGISC were randomised to receive daily supplementation with a triple-strain bifidobacterial probiotic (n = 30) or placebo (n = 31) until discharge. Stool microbiota was analysed using 16S ribosomal RNA gene sequencing on samples collected before (T1), 1 week (T2), and 2 weeks (T3) after supplementation and before discharge (T4). The primary outcome was the sum of the relative abundance of potentially pathogenic families of Clostridiaceae, Enterobacteriaceae, Enterococcaceae, Pseudomonaceae, Staphylococcaeae, Streptococcaceae, and Yersiniaceae at T3. RESULTS: The median gestational age [38 weeks (IQR: 37.1–38.9)] was similar in both groups. The probiotic group had lower rates of caesarean deliveries (40% versus 70%, p = 0.02). The relative abundance of potentially pathogenic families was lower in the probiotic group compared to placebo at T3 [(median: 50.4 (IQR: 26.6–67.6) versus 67.1 (IQR: 50.9–96.2); p = 0.04). Relative abundance of Bifidobacteriaceae was higher in the probiotic group at T3 [(median: 39.8 (IQR: 24.9–52.1) versus 0.03 (IQR 0.02–2.1); p < 0.001). Stratified analysis continued to show a higher abundance of Bifidobacteriaceae in the probiotic group, irrespective of the mode of delivery. CONCLUSIONS: Probiotic supplementation attenuated gut dysbiosis in neonates with CGISC. TRIAL REGISTRATION: http://www.anzctr.org.au (ACTRN12617001401347). IMPACT: ● Probiotic supplementation attenuates gut dysbiosis and improves stool short-chain fatty acid levels in neonates with congenital gastrointestinal surgical conditions. ● This is the second pilot RCT of probiotic supplementation in neonates with congenital gastrointestinal conditions. ● These findings will pave the way for conducting multicentre RCTs in this area.
URI: https://hdl.handle.net/10356/162587
ISSN: 0031-3998
DOI: 10.1038/s41390-021-01884-x
Rights: © Crown 2021. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:SCBE Journal Articles

SCOPUSTM   
Citations 50

1
Updated on Nov 25, 2022

Page view(s)

10
Updated on Nov 30, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.